Phenytoin and phenobarbital inhibit human HERG potassium channels

Epilepsy Research

Volumn 55, Issue 1-2, 2003, Pages 147-157

  Danielsson, Bengt R ^a   Lansdell, Kate ^b   Patmore, Leslie ^b   Tomson, Torbjörn ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carbamazepine; HERG; IKr; Phenobarbital; Phenytoin; Sudden death

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; POTASSIUM CHANNEL;

ARRHYTHMOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG MECHANISM; EMBRYO; EMBRYO CELL; EPILEPSY; GENE; GENE EXPRESSION; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN ETHER A GO GO RELATED GENE; IC 50; ION CURRENT; KIDNEY CELL; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; SEIZURE; SUDDEN DEATH;

EID: 0042431784     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(03)00119-0     Document Type: Article

References (34)

1. Abrahamsson C., Palmer M., Ljung B., Duker G., Bäärnhielm C., Carlsson L., Danielsson B. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc. Res. 28:1994;337-344.
2. Azarbayjani F., Danielsson B.R. Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: a common teratogenic mechanism for antiepileptic drugs? Teratology. 57:1998;117-126.
3. Canadian Minister of Health, 2001. Therapeutic Products Directorate Guidance Document: assessment of the QT prolongation potential of non-antiarrhytmic drugs (ref. type: internet communication).
4. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:1995;795-803.
5. Danielsson B.R., Azarbayjani F., Sköld A.C., Webster W.S. Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology. 56:1997;271-281.
6. Davies M.P., An R.H., Doevendans P., Kubalak S., Chien K.R., Kass R.S. Developmental changes in ionic channel activity in the embryonic murine heart. Circ. Res. 78:1996;15-25.
7. EMEA, 1997. Points to consider: the assessment of the potential for QT interval prolongation by non-cardivascular medicinal products (EMEACPMPI986I96). Internet.
8. Ficker D.M., So E.L., Shen W.K., Annegers J.F., O'Brien P.C., Cascino G.D., Belau P.G. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology. 51:1998;1270-1274.
9. van Haarst A.D., 't Klooster G.A., van Gerven J.M., Schoemaker R.C., van Oene J.C., Burggraaf J., Coene M.C., Cohen A.F. The influence of cisapride and clanthromycin on QT intervals in healthy volunteers. Clin. Pharmacol. Ther. 64:1998;542-546.
10. Hancox J.C., Witchel H.J. Psychotropic drugs, HERG, and the heart. Lancet. 356:2000;428.
11. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences (see comments). JAMA. 269:1993;1513-1518. (erratum appears in JAMA 1993 269 (16), 2088).
12. ICH, 2001. ICHS7B: nonclinical studies for assessing risk of cardiac arrhythmia associated with delayed ventricular repolarization (QT interval prolongation) for human pharmaceuticals. Step 2 (ref. type: internet communication).
13. Langan Y., Nashef L., Sander J.W. Sudden unexpected death in epilepsy: a series of witnessed deaths. J. Neurol. Neurosurg. Psychiatry. 68:2000;211-213.
14. Lhatoo S.D., Johnson A.L., Goodridge D.M., MacDonald B.K., Sander J.W., Shorvon S.D. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann. Neurol. 49:2001;336-344.
15. Mackenzie Bacon, G., 1868. On the modes of death in epilepsy. Lancet, 1155-1156.
16. Malik M., Camm A.J. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 24:2001;323-351.
17. Mohammad S., Zhou Z., Gong Q., January C.T. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 273:1997;H2534-H2538.
18. Nashef L., Walker F., Allen P., Sander J.W., Shorvon S.D., Fish D.R. Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy. J. Neurol. Neurosurg. Psychiatry. 60:1996;297-300.
19. Nilsson L., Farahmand B.Y., Persson P.G., Thiblin I., Tomson T. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet. 353:1999;888-893.
20. Nilsson L., Bergman U., Diwan V., Farahmand B.Y., Persson P.G., Tomson T. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia. 42:2001;667-673.
21. Orringer C.E., Eustace J.C., Wunsch C.D., Gardner L.B. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N. Engl. J. Med. 297:1977;796-799.
22. Pedley T.A., Hauser W.A. Sudden death in epilepsy: a wake-up call for management. Lancet. 359:2002;1790-1791.
23. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
24. Tennis P., Cole T.B., Annegers J.F., Leestma J.E., McNutt M., Rajput A. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan. Can. Epilepsia. 36:1995;29-36.
25. Tomson T., Kennebck G. Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia. 38:1997;S48-S51.
26. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 269:1995;92-95.
27. Vereecke J., Carmeliet E. The effect of external pH on the delayed rectifying K+ current in cardiac ventricular myocytes. Pflugers. Arch. 439:2000;739-751.
28. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
29. Walczak T.S., Leppik I.E., D'Amelio M., Rarick J., So E., Ahman P., Ruggles K., Cascino G.D., Annegers J.F., Hauser W.A. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology. 56:2001;519-525.
30. Wang L., Feng Z.P., Kondo C.S., Sheldon R.S., Duff H.J. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ. Res. 79:1996;79-85.
31. Webster W.S., Brown-Woodman P.D., Snow M.D., Danielsson B.R. Teratogenic potential of almokalant, dofetilide, and D-sotalol: drugs with potassium channel blocking activity. Teratology. 53:1996;168-175.
32. Webster R., Leishman D., Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de point. Curr. Opin. Drug Discov. Dev. 1:2002;116-128.
33. Witchel H.J., Hancox J.C. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol. 27:2000;753-766.
34. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 74:1998;230-241.